Cargando…

Comparing the Efficacy of Ceftazidime and Meropenem in Treatment of Febrile Neutropenia in Pediatric Patients with Cancer

BACKGROUND: In cancer patients, various infections were developed due to severe neutropenia resulted from chemotherapy. Ceftazidime is commonly used as monotherapy of cancer patients with fever and neutropenia. Meropenem is a new carbapenem with more extended antibacterial spectrum including anaerob...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferdosian, F, Ghiliyan, R, Hashemi, A, Akhondzadeh, B, Gholampoor, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shahid Sadoughi University of Medical Sciences 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921881/
https://www.ncbi.nlm.nih.gov/pubmed/24575280
_version_ 1782303373160087552
author Ferdosian, F
Ghiliyan, R
Hashemi, A
Akhondzadeh, B
Gholampoor, E
author_facet Ferdosian, F
Ghiliyan, R
Hashemi, A
Akhondzadeh, B
Gholampoor, E
author_sort Ferdosian, F
collection PubMed
description BACKGROUND: In cancer patients, various infections were developed due to severe neutropenia resulted from chemotherapy. Ceftazidime is commonly used as monotherapy of cancer patients with fever and neutropenia. Meropenem is a new carbapenem with more extended antibacterial spectrum including anaerobes. It provides better coverage against gram positives. This trial compared the efficacy and safety of meropenem with ceftazidime as empirical monotherapy for febrile neutropenia in pediatric patients with cancer. MATERIALS AND METHODS: A prospective, double-blind, randomized clinical trial was conducted at Departments of Pediatric Haematology/Oncology, University Hospitals, Yazd, Iran, during the years 2012 to 2013. A total of 48 cancer patients participated in the trial. RESULT: In this study, 26 patients (54.16%) were treated by ceftazidime and 22 patients (45.84%) by meropenem. Mean duration of fever in those who responded to treatment in ceftazidime group was 19.43+/-31.04 hours, and in meropenem group was 16.53+/-28.77 hours (P-value = 0.965). CONCLUSION: Finding of this study indicate that ceftazidime and meropenem have similar efficacy in treatment of fever and sever neutropenia. Due to more availability and lower cost of ceftazidime than meropenem, ceftazidime is suggested as a first line treatment in fever and neutropenia.
format Online
Article
Text
id pubmed-3921881
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Shahid Sadoughi University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-39218812014-02-26 Comparing the Efficacy of Ceftazidime and Meropenem in Treatment of Febrile Neutropenia in Pediatric Patients with Cancer Ferdosian, F Ghiliyan, R Hashemi, A Akhondzadeh, B Gholampoor, E Iran J Ped Hematol Oncol Original Article BACKGROUND: In cancer patients, various infections were developed due to severe neutropenia resulted from chemotherapy. Ceftazidime is commonly used as monotherapy of cancer patients with fever and neutropenia. Meropenem is a new carbapenem with more extended antibacterial spectrum including anaerobes. It provides better coverage against gram positives. This trial compared the efficacy and safety of meropenem with ceftazidime as empirical monotherapy for febrile neutropenia in pediatric patients with cancer. MATERIALS AND METHODS: A prospective, double-blind, randomized clinical trial was conducted at Departments of Pediatric Haematology/Oncology, University Hospitals, Yazd, Iran, during the years 2012 to 2013. A total of 48 cancer patients participated in the trial. RESULT: In this study, 26 patients (54.16%) were treated by ceftazidime and 22 patients (45.84%) by meropenem. Mean duration of fever in those who responded to treatment in ceftazidime group was 19.43+/-31.04 hours, and in meropenem group was 16.53+/-28.77 hours (P-value = 0.965). CONCLUSION: Finding of this study indicate that ceftazidime and meropenem have similar efficacy in treatment of fever and sever neutropenia. Due to more availability and lower cost of ceftazidime than meropenem, ceftazidime is suggested as a first line treatment in fever and neutropenia. Shahid Sadoughi University of Medical Sciences 2013 2013-07-22 /pmc/articles/PMC3921881/ /pubmed/24575280 Text en © 2013: Iranian Journal of Pediatric Hematology Oncology This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ferdosian, F
Ghiliyan, R
Hashemi, A
Akhondzadeh, B
Gholampoor, E
Comparing the Efficacy of Ceftazidime and Meropenem in Treatment of Febrile Neutropenia in Pediatric Patients with Cancer
title Comparing the Efficacy of Ceftazidime and Meropenem in Treatment of Febrile Neutropenia in Pediatric Patients with Cancer
title_full Comparing the Efficacy of Ceftazidime and Meropenem in Treatment of Febrile Neutropenia in Pediatric Patients with Cancer
title_fullStr Comparing the Efficacy of Ceftazidime and Meropenem in Treatment of Febrile Neutropenia in Pediatric Patients with Cancer
title_full_unstemmed Comparing the Efficacy of Ceftazidime and Meropenem in Treatment of Febrile Neutropenia in Pediatric Patients with Cancer
title_short Comparing the Efficacy of Ceftazidime and Meropenem in Treatment of Febrile Neutropenia in Pediatric Patients with Cancer
title_sort comparing the efficacy of ceftazidime and meropenem in treatment of febrile neutropenia in pediatric patients with cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921881/
https://www.ncbi.nlm.nih.gov/pubmed/24575280
work_keys_str_mv AT ferdosianf comparingtheefficacyofceftazidimeandmeropenemintreatmentoffebrileneutropeniainpediatricpatientswithcancer
AT ghiliyanr comparingtheefficacyofceftazidimeandmeropenemintreatmentoffebrileneutropeniainpediatricpatientswithcancer
AT hashemia comparingtheefficacyofceftazidimeandmeropenemintreatmentoffebrileneutropeniainpediatricpatientswithcancer
AT akhondzadehb comparingtheefficacyofceftazidimeandmeropenemintreatmentoffebrileneutropeniainpediatricpatientswithcancer
AT gholampoore comparingtheefficacyofceftazidimeandmeropenemintreatmentoffebrileneutropeniainpediatricpatientswithcancer